Balancing Analgesic Effects and Abuse Liability in Older Adults: A Randomized, Placebo-Controlled Trial of Oral and Vaporized Δ9-Tetrahydrocannabinol
En palabras de los autores
Cannabis use is rising fastest among older adults in the U.S., and pain is among the most common reasons they use it. No trial, however, has measured the trade-off between the analgesic and abuse-related effects of {Delta}9-tetrahydrocannabinol ({Delta}9-THC) in this population. In a randomized, double-blind, placebo-controlled trial, 20 adults aged 65 and older were assigned to oral {Delta}9-THC (placebo, 5, 10 mg) or vaporized {Delta}9-THC (placebo, 2, 4 mg) across three eight-hour sessions in counterbalanced order. We assessed laboratory-evoked pain sensitivity using quantitative sensory testing, abuse liability using subjective drug effects and reinforcement value, and also sampled plasma {Delta}9-THC and 11-OH-THC. Analgesia and abuse liability outcomes were measured repeatedly within each session. On a pain sensitivity index, oral 5 mg relieved pain relative to placebo (p=.040), although the oral arm's overall dose effect was not significant (p=.108); oral 10 mg and both vaporized doses did not differ from placebo. Subjective effects increased with dose and were greatest after vaporization, whereas reinforcement value increased only after vaporized 4 mg. After oral 5 mg, analgesia exceeded placebo at every assessment (60-360 min), while its pleasurable effects peaked at 150 min. Vaporized {Delta}9-THC produced pleasurable effects within 30 min but did not significantly change thermal pain sensitivity. While abuse liability tracked {Delta}9-THC exposure, analgesia showed no significant association, and all adverse events occurred at vaporized 4 mg. These findings suggest dose and route selection may help maximize {Delta}9-THC analgesia while minimizing abuse liability, a strategy that warrants evaluation in clinical populations.
En palabras simples Resumen con IA
Los investigadores probaron cómo diferentes dosis y formas de THC afectan el dolor y el potencial de uso indebido en 20 adultos de 65 años o más. Una dosis oral de 5 mg redujo el dolor en comparación con el placebo, pero dosis orales más altas y dosis vaporizadas no aliviaron significativamente el dolor. Los autores sugieren que elegir dosis y métodos de administración específicos puede ayudar a maximizar el alivio del dolor mientras se minimiza el riesgo de uso indebido.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale. Se eliminaron 2 oraciones por no estar respaldadas por el abstract.
Apareció: jueves, 5 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.